Zolinza Merck & Co., Inc. - Treatment for Cutaneous T-cell Lymphoma

Zolinza is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin’s lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.

Posted: October 2006

Related Articles:

Zolinza (vorinostat) FDA Approval History

View comments

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web2)